Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) guidelines for the diagnosis of invasive fungal infections. 2010 Update;Recomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 1, 2011, Pages

  Ayats, Josefina ^a   Martín Mazuelos, Estrella ^b   Pemán, Javier ^c   Quindós, Guillermo ^d   Sánchez, Fernando ^e   García Rodríguez, Julio ^f   Guarro, Josep ^g   Guinea, Jesús ^h   Linares, María J ⁱ   Pontón, José ^d   Rodríguez Tudela, Juan L ^j   Cuenca Estrella, Manuel ^j   Aguado, José M ^k   Almirante, Benito ^l   Alvarez Lerma, Francisco ^m   Borges, Marcio ⁿ   Carratalá, Jordi ^a   Cervera, Carlos ^o   De La Cámara, Rafael ^p   De La Torre Cisneros, Julián ⁱ   Fortún, Jesús ^q   Garnacho, José ^r   Gavaldá, Joan ^s   Lassaletta, Alvaro ^b   León, Cristóbal ^h   Lizasoain, Manuel ^k   Madero, Luis ^b   Martín Dávila, Pilar ^q   Mensa, José ^o   Moreno, Asunción ^o   Muñoz, Patricia ^t   Amador, José T Ramos ^c   Rovira, Montserrat ^o   Ruiz, Isabel ^l   Ruiz Contreras, Jesús ^k   Salavert, Miguel ^u   Sanz, Miguel A ^u   Vázquez, Lourdes ^u   more..

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ UNIVERSITY OF CÓRDOBA   (Spain)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL DEL MAR   (Spain)

ⁿ HOSPITAL SON LLÀTZER   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

^p Hospital de la Zarzuela   (Spain)

^q HOSPITAL RAMÓN Y CAJAL   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^s HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^t HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^u HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Beta glucan; Diagnostic PCR; Early diagnosis; Galactomannan; Invasive fungal infection

Indexed keywords

DNA; FUNGUS ANTIGEN;

ANTIFUNGAL SUSCEPTIBILITY; CONFERENCE PAPER; DIAGNOSTIC TEST; FUNGUS CULTURE; FUNGUS IDENTIFICATION; MICROSCOPY; NONHUMAN; PRACTICE GUIDELINE; SYSTEMIC MYCOSIS;

EID: 79952364109     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.08.005     Document Type: Conference Paper

References (155)

1. Rezusta A, Sánchez A, Gil J. Fundamentos básicos para el diagnóstico micológico. En: Pemán J, Martín-Mazuelos E, Rubio MC, editores. Guía práctica de identificación y diagnóstico en Micologia Clínica. Bilbao: Revista Iberoamericana de Micología; 2001. p. 3.1-17.
2. Hazen KC (ed. section). Mycology and Antifungal Susceptibility Testing. En: Isenberg HD, editor. Clinical Microbiology Procedures Handbook. 2th ed. Washington DC: ASM Press; 2004. p. 8.1.1.-10.7.
3. Reimer LG, Wilson ML, Weinstein MP. Update on detecction of bacteremia and fungemia. Clin Microbiol Rev. 1997;10:444-65.
4. Clinical and Laboratory Standards Institute. Principles and procederes for blood cultures, approved guideline. CLSI Document M47-A. Wayne, PA: Clinical and Laboratory Standards Institute: 2007.
5. Cockerill FR, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, et al. Optimal Testing Parameters for Blood Cultures. Clin Infec Dis. 2004;38:1724-30. (Pubitemid 38781664)
6. a ed. Bilbao: Revista Iberoamericana de Micología; 2007, 5.1-12.
7. Shea YR. Algorithms for Detection and Identification of Fungi. En: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. 9th ed. Washington DC: American Society for Microbiology; 2007. p. 1745-61.
8. a ed. Bilbao: Revista Iberoamericana de Micología; 2007, 14a.1-16.
9. Brown MS, Wu TC. The gram stain morphology of fungi, mycobacteria, and Pneumocystis carinii. J Med Technol. 1986;3:495-9. (Pubitemid 16011600)
10. Mayayo E. Diagnóstico histopatológico de las micosis. Rev Iberoam Micol. 2004;21:1-9.
11. Cushion MT. Pneumocystis. En: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. 9th ed. Washington DC: American Society for Microbiology; 2007. p. 1789-801.
12. Marcon MJ, Powell DA. Human infections due to Malassezia spp. Clin Microbiol Rev. 1992;5:101-19.
13. Denning DW, Stevens DA, Hamilton JR. Comparison of Guizotia abyssinica seed extract (birdseed) agar with conventional media for selective identification of Cryptococcus neoformans in patients with acquired immunodeficiency syndrome. J Clin Microbiol. 1990;28:2565-7. (Pubitemid 20353541)
14. Jabra-Rizk MA, Brenner TM, Romagnoli M, Baqui AA, Merz WG, Falkler Jr WA, et al. Evaluation of a reformulated CHROMagar Candida. J Clin Microbiol. 2001;39:2015-6. (Pubitemid 32417068)
15. Lyon R, Woods G. Comparison of the BacT/Alert and Isolator blood culture systems for recovery of fungi. Am J Clin Pathol. 1995;103:660-2.
16. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824-33. (Pubitemid 33105120)
17. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35:1526-31.
18. Pasqualotto AC. Candida and the paediatric lung. Ped Resp Rev. 2009;10:186-91.
19. Safdar A, Singhal S, Mehta J. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). Cancer. 2004;100:2456-61.
20. Bodey GP. Fungal infections in immunocompromised patients. III. Emerging pathogens and recent therapeutic advances. Infect Dis Rev. 2000;2:12-6.
21. Boutati EI, Anaisse EJ, Fusarium. a significant emerging pathogen in patients wiyh hematologic malignancy: ten year's experience at a Cancer Center and implications for manegement. Blood. 1997;90:999-1008. (Pubitemid 27314133)
22. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis. 2000;31:188-9. (Pubitemid 32268963)
23. Larone DH. Medically important fungy: a guide to identification. 4th ed. Washington DC: ASM Press; 2002.
24. a ed. Bilbao: Revista Iberoamericana de Micología; 2007. p. 11.1-11.1.
25. Linares MJ, Charriel G, Solís F, Casal M. CHROMAgar Candida mas fluconazol. Comparación con técnicas de microdilución. Enferm Infec Microbiol Clín. 2003;21:493-7.
26. Sendid B, Francois N, Standaert A, Dehecq E, Zerimech f, Camus D, Poulain D. Prospective evaluation of the new chromogenic medium CandiSelect 4 for differentiation and presumptive identification of the major pathogenic Candida species. J Med Microbiol. 2007;56:495-9. (Pubitemid 46626567)
27. He F, Zhong M. New MSPQC-PLS method for the early clinic identification of commonly encountered Candida species. Talanta. 2010;15:1210-5.
28. Szabó Z, Tóth B, Kovács M, Kardos G, Maráz A, Rozgonyi F, Majoros L. Evaluation of thenewMicronaut-Candida system compared to the APIID32C method yeast identification. J Clin Microbiol. 2008;46:1824-5. (Pubitemid 351657234)
29. Peman J, Aparisi N, Garcia-Esteban C, Gobernado M. Utilidad de una nueva técnica comercial. GLABRATA RTT, para la identificación rápída de Candida glabrata. Rev Iberoam Micol. 2004;21:82-4.
30. Sahand IH, Ortiz R, Pemán J, Moragues MD, Quindós G, Pontón J. Identificación ráida de Candida dubliniensis mediante el test Bichro-Dubli. Enferm Infecc Microbiol. 2007;25:576-8. (Pubitemid 350070769)
31. Pincus DH, Orenga S, Chatellier S. Yeast identification-past, present, and future methods. Med Mycol. 2007;45:97-121. (Pubitemid 46371953)
32. Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis. 2008;21:421-5.
33. Zaragoza R, Pemán J. Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol. 2006;23:59-63. (Pubitemid 44133520)
34. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (13) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41: 654-9.
35. Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H, Hedstrom U. Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol. 2009;58:606-15.
36. Verduyn Lunel FM, Donnelly JP, van der Lee HA, Blijlevens NM, Verweij PE. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009;15:380-6.
37. Moragues MD, Ortiz N, Iruretagoyena JR, García-Ruiz JC, Amutio E, Rojas A, et al. Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis. Enferm Infecc Microbiol Clin. 2004;22:83-8. (Pubitemid 38585446)
38. Iruretagoyena JR, Regulez P, Quindós G, Pontón J. Antibodies to Candida albicans germ tubes in two intensive care patients with invasive candidiasis. Rev Iberoam Micol. 2000;17:93-6.
39. Zaragoza R, Pemán J, Quindós G, Iruretagoyena JR, Cuetara MS, Ramirez P, et al. Kinetic Patterns of Candida albicans Germ Tube Antibody (CAGTA) in Critically Ill Patients: Influence on Mortality. Clin Vaccine Immunol. 2009.
40. Prince HE, Yeh C, Alem N, Asalkhou M, Hamedi N, Alem N, et al. Evaluation of enzyme-linked immunosorbent assays for detecting circulating antibodies to Candida albicans. J Clin Lab Anal. 2008;22:234-8.
41. Sendid B, Dotan N, Nseir S, Savaux C, Vandewalle P, Standaert A, et al. Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. Clin Vaccine Immunol. 2008;15:1868-77.
42. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (13)-beta- D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864-70.
43. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky- Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol. 2006;44:267-72. (Pubitemid 43771933)
44. Lain A, Elguezabal N, Moragues MD, Garcia-Ruiz JC, del PA, Pontón J. Contribution of serum biomarkers to the diagnosis of invasive candidiasis. Expert Rev Mol Diagn. 2008;8:315-25. (Pubitemid 351724710)
45. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnosticperformance of the (1→3)-β-D-glucan assay for invasive fungal disease. Clin Infect Dis. 2009;49:1650-9.
46. Metwally L, Fairley DJ, Coyle PV, Hay RJ, Hedderwick S, McCloskey B, et al. Comparison of serum and whole-blood specimens for the detection of Candida DNA in critically ill, non-neutropenic patients. J Med Microbiol. 2008;57:1269-72.
47. Lau A, Halliday C, Chen SCA, Playford EG, Stanley K, Sorrell TC. Comparison of whole blood, serum and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol. 2009;48:811-6.
48. Lin MT, Lu HC, Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis. 2001;33:1621-7.
49. Klingspor L, Jalal S. Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. Clin Microbiol Infect. 2006;12:745-53. (Pubitemid 43983799)
50. McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O'Neill HJ, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008;46:890-6. (Pubitemid 351417192)
51. Westh H, Lisby G, Breysse F, Boddinghaus B, Chomarat M, Gant V, et al. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect. 2009;15:544-51.
52. Dierkes C, Ehrenstein B, Siebig S, Linde HJ, Reischl U, Salzberger B. Clinical impact of a commercially available multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis. BMC Infect Dis. 2009;9: 126.
53. von Lilienfeld-Toal M, Lehmann LE, Raadts AD, Hahn-Ast C, Orlopp KS, Marklein G, et al. Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol. 2009;47:2405-10.
54. Lau A, Sorrell TC, Chen S, Stanley K, Iredell J, Halliday C. Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. J Clin Microbiol. 2008;46:3021-7.
55. Alexander BD, Ashley ED, Reller LB, Reed SD. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis. 2006;54:277-82.
56. García-Ruiz JC, Arilla MC, Regulez P, Quindós G, Álvarez A, Pontán J. Detection of antibodies to Candida albicans germ tubes for diagnosis and therapeutic monitoring of invasive candidiasis in patients with hematologic malignancies. J Clin Microbiol. 1997;35:3284-7. (Pubitemid 27505760)
57. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-Dglucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199-205. (Pubitemid 38971490)
58. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43:5957-62. (Pubitemid 43100644)
59. Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A. Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol. 2006;23:209-15.
60. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2009;47:129-33.
61. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21.
62. Smith PB, Benjamin Jr DK, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol. 2007;14:924-5.
63. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Preemptive treatment of fungal infection based on plasma (13)beta-D-glucan levels after liver transplantation. Infection. 2007;35:346-51.
64. Segal BH, Aspergillosis. N Engl J Med. 2009;360:1870-4.
65. Menninck-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4:349-57. (Pubitemid 38692699)
66. Fortún J, Martín-Dávila P, Álvarez ME, Sánchez-Sousa A, Quereda C, Navas E, et al., the Ramón y Cajal Hospital's Liver Transplant Group. Aspergillus antigenemia sándwich- enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation. 2001;71:145-9.
67. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604-10. (Pubitemid 32217224)
68. Boutboul F, Alberti C, Leblanc T, Sulahian A, Gluckman E, Derouin F, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002;34:939-43. (Pubitemid 34229762)
69. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002;20:1898-906. (Pubitemid 34273282)
70. Pazos C, Pontón J, del Palacio A. Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43:299-305. (Pubitemid 40096315)
71. Maertens JA, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou V, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. 2007;44:1329-36. (Pubitemid 46729195)
72. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27-34.
73. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, Barlogie B, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with haematological cancer: Clinical and research implications. Clin Infect Dis. 2008;46:1412-22. (Pubitemid 351589942)
74. Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688-93.
75. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol. 2003;121:448-57. (Pubitemid 36628336)
76. Kawazu M, Kanda Y, Nannya Y, Aoki K, KurokawaM, Chiba S, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta- D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42:2733-41. (Pubitemid 38747529)
77. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomann enzyme immunoassay. Clin Infect Dis. 2005;40:1762-9. (Pubitemid 40799945)
78. El Saleeby C, Allison K, Knapp K, Walsh T, Hayden R. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialisis. J Clin Microbiol. 2005;43:3560-3. (Pubitemid 40981395)
79. Klont RR, Mennink-Kersten MA, Ruegebrink D, Rijs AJ, Blijlevens NM, Donnelly JP, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis. 2006;43:e23-5.
80. Husain S, Paterson DL, Studer SM, Crespo M, Pilewski J, Durkin M, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation. 2007;83:1330-6. (Pubitemid 46800308)
81. Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, et al. H. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45:1759-65. (Pubitemid 46933903)
82. KamiM, Tanaka Y, Kanda Y, Ogawa S, Masumoto T, Ohtomo K, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1→3)- beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica. 2000;85:745-52. (Pubitemid 30617109)
83. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46:878-85.
84. Marty FM, Koo S. Role of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol. 2008;13:1-8.
85. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev. 2006;19:165-256. (Pubitemid 43158452)
86. Lass-Flörl C, Gunsilius E, Gastl G, Bonatti H, Freund MC, Gschwendtner A, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol. 2004;42:4154-7. (Pubitemid 39296138)
87. Cuenca-Estrella M, Meije Y, Díaz-Pedroche C, Gómez- López A, Buitrago MJ, Bernal-Martínez L, et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia. J Clin Microbiol. 2009;47:379-84.
88. Hebart H, Klingspor L, Klingebiel T, Loeffler J, Tollemar J, Ljungman P, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant. 2009;43:553-61.
89. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:89-96.
90. Klingspor L, Loeffler J. Aspergillus PCR formidable challenges and progress. Med Mycol. 2009;47 Suppl. 1:S241-7.
91. Steinmann J, Buer J, Rath PM, Paul A, Saner F. Invasive aspergillosis in two liver transplant recipients: diagnosis by SeptiFast. Transpl Infect Dis. 2009;11:175-8.
92. Gadea I, Cuenca-Estrella M. Guidelines for fungal diagnoses and antifungal sensitivity studies. Enferm Infecc Microbiol Clin. 2004;22:32-9. (Pubitemid 38374125)
93. Temstet A, Roux P, Poirot JL, Ronin O, Dromer F. Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J Clin Microbiol. 1992;30:2544-50.
94. Fekkar A, Brun S, D'Ussel M, Uzunov M, Cracco C, Dhedin N, et al. Serum cross-reactivity with Aspergillus galactomannan and cryptococcal antigen during fatal disseminated Trichosporon dermatis infection. Clin Infect Dis. 2009;49:1457-8.
95. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21.
96. Prevost E, Newell R. Commercial cryptococcal latex kit: clinical evaluation in a medical center hospital. J Clin Microbiol. 1978;8:529-33. (Pubitemid 9052789)
97. Babady NE, Bestrom JE, Jespersen DJ, Jones MF, Beito EM, Binnicker MJ, et al. Evaluation of three commercial latex agglutination kits and a commercial enzyme immunoassay for the detection of cryptococcal antigen. Med Mycol. 2009;47:336-8.
98. Frank UK, Nishimura SL, Li NC, Sugai K, Yajko DM, Hadley WK, et al. Evaluation of an enzyme immunoassay for detection of cryptococcal capsular polysaccharide antigen in serum and cerebrospinal fluid. J Clin Microbiol. 1993;31:97-101. (Pubitemid 23006586)
99. Gade W, Hinnefeld SW, Babcock LS, Gilligan P, Kelly W, Wait K, et al. Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol. 1991;29:1616-9.
100. Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA, Henderson H, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis. 2008;27:937-43.
101. Osawa R, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. Transplantation. 2010;89:69-74.
102. Veron V, Simon S, Blanchet D, Aznar C. Real-time polymerase chain reaction detection of Cryptococcus neoformans and Cryptococcus gattii in human samples. Diagn Microbiol Infect Dis. 2009;65:69-72.
103. Enache-Angoulvant A, Chandenier J, Symoens F, Lacube P, Bolognini J, Douchet C, et al. Molecular identification of Cryptococcus neoformans serotypes. J Clin Microbiol. 2007;45:1261-5. (Pubitemid 46626495)
104. Rickerts V, Just-Nubling G, Konrad F, Kern J, Lambrecht E, Bohme A, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis. 2006;25:8-13. (Pubitemid 43207322)
105. Kasai M, Harrington SM, Francesconi A, Petraitis V, Petraitiene R, Beveridge MG, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol. 2008;46:3690-702.
106. Khot PD, Fredricks DN. PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther. 2009;7:1201-21.
107. Asociacion Española de Micologia. In: Pemán J, Martín-Mazuelos E, Rubio MC, editors. Guía práctica de identificación y diagnóstico en Micología clínica. Bilbao: Revista Iberoamericana de Micologia; 2001.
108. Castelli MV, Buitrago MJ, Bernal-Martínez L, Gómez- López A, Rodríguez- Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol. 2008;46:3412-6.
109. Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009;135:655-61.
110. Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax. 2008;63:154-9. (Pubitemid 351236483)
111. Marty FM, Koo S, Bryar J, Baden LR. (1->3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med. 2007;147:70-2. (Pubitemid 351664641)
112. Wheat LJ, Garringer T, Brizendine E, Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory. Diagn Microbiol Infect Dis. 2002;43:29-37. (Pubitemid 34607514)
113. Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther. 2006;6:1207-21.
114. Hage CA, Davis TE, Fuller D, Egan L, Witt III JR, Wheat LJ, et al. Diagnosis of histoplasmosis by antigen detection in bronchoalveolar fluid. Chest. 2009.
115. Swartzentruber S, Rhodes L, Kurkjian K, Zahn M, Brandt ME, Connolly P, et al. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin Infect Dis. 2009;49:1878-82.
116. Buitrago MJ, Berenguer J, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Detection of imported histoplasmosis in serum of HIV-infected patients using a real-time PCR-based assay. Eur J Clin Microbiol Infect Dis. 2006;25: 665-8. (Pubitemid 44526878)
117. Buitrago MJ, Gomez-Lopez A, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. Assessment of a quantitative PCR method for clinical diagnosis of imported histoplasmosis. Enferm Infecc Microbiol Clin. 2007;25:16-22. (Pubitemid 46232685)
118. Wheat LJ. Approach to the diagnosis of the endemic mycoses. Clin Chest Med. 2009;30:379-89, viii.
119. Durkin M, Witt J, LeMonte A, Wheat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol. 2004;42:4873-5. (Pubitemid 39362430)
120. Hage CA, Davis TE, Egan L, Parker M, Fuller D, Lemonte AM, et al. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzymelinked immunoassay. Respir Med. 2007;101:43-7. (Pubitemid 44835243)
121. Bialek R, Gonzalez GM, Begerow D, Zelck UE. Coccidioidomycosis and blastomycosis: advances in molecular diagnosis. FEMS Immunol Med Microbiol. 2005;45:355-60. (Pubitemid 41247772)
122. Durkin M, Estok L, Hospenthal D, Crum-Cianflone N, Swartzentruber S, Hackett E, et al. Detection of Coccidioides antigenemia following dissociation of immune complexes. Clin Vaccine Immunol. 2009;16:1453-6.
123. Pappagianis D. Serologic studies in coccidioidomycosis. Semin Respir Infect. 2001;16:242-50. (Pubitemid 34031646)
124. da Silva SH, Grosso DM, Lopes JD, Colombo AL, Blotta MH, Queiroz-Telles F, et al. Detection of Paracoccidioides brasiliensis gp70 circulating antigen and follow-up of patients undergoing antimycotic therapy. J Clin Microbiol. 2004;42:4480-6. (Pubitemid 39362359)
125. Marques-da-Silva SH, Colombo AL, Blotta MH, Queiroz-Telles F, Balthazar AB, Lopes JD, et al. Diagnosis of Paracoccidioidomycosis by detection of antigen and antibody in bronchoalveolar lavage fluids. Clin Vaccine Immunol. 2006;13:1363-6. (Pubitemid 46086903)
126. Marques da Silva SH, Colombo AL, Blotta MH, Lopes JD, Queiroz-Telles F, Pires DC. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. J Clin Microbiol. 2003;41:3675-80. (Pubitemid 36994701)
127. Buitrago MJ, Merino P, Puente S, Gomez-Lopez A, Arribi A, Zancope-Oliveira RM, et al. Utility of Real-time PCR for the detection of Paracoccidioides brasiliensis DNA in the diagnosis of imported paracoccidioidomycosis. Med Mycol. 2009:1-4.
128. Chaiyaroj SC, Chawengkirttikul R, Sirisinha S, Watkins P, Srinoulprasert Y. Antigen detection assay for identification of Penicillium marneffei infection. J Clin Microbiol. 2003;41:432-4. (Pubitemid 36098613)
129. Panichakul T, Chawengkirttikul R, Chaiyaroj SC, Sirisinha S. Development of a monoclonal antibody-based enzyme-linked immunosorbent assay for the diagnosis of Penicillium marneffei infection. Am J Trop Med Hyg. 2002;67:443-7. (Pubitemid 35303871)
130. Pornprasert S, Praparattanapan J, Khamwan C, Pawichai S, Pimsarn P, Samleerat T, et al. Development of TaqMan real-time polymerase chain reaction for the detection and identification of Penicillium marneffei. Mycoses. 2009;52:487-92.
131. Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3138-41.
132. Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, et al. Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol. 2009;47:877-84.
133. Asociacion Española de Micologia. Guía práctica de identificación y diagnóstico en Micología clínica. Pemán J, Martín-Mazuelos E, Rubio MC, editores. 2001. Bilbao, Revista Iberoamericana de Micologia.
134. Guarro J, GeneJ, Stchigel AM. Developments in fungal taxonomy. Clin Microbiol Rev. 1999;12:454-500. (Pubitemid 29330140)
135. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Approved Standard-Third Edition. CLSI document M27-A3. Clinical Laboratory Standards Institute. 2008. Wayne, Pennsylvania, USA.
136. Canton E, Peman J, Espinel-Ingroff A, Martin-Mazuelos E, Carrillo-Munoz A, Martinez JP. Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. J Antimicrob Chemother. 2008;61:135-8 (6).
137. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi;Approved Standard- Second Edition. CLSI document M38-A2. Clinical Laboratory Standards Institute. 2008. Wayne, Pennsylvania, USA.
138. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, et al. EUCAST Technical Note on fluconazole. Clin Microbiol Infect. 2008;14:193-5.
139. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, et al. EUCAST Technical Note on voriconazole - Subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European committee for antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2008;14:985-7.
140. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, et al. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398-405. (Pubitemid 351356536)
141. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52:3022-8.
142. Cuesta I, Bielza C, Larranaga P, Cuenca-Estrella M, Laguna F, Rodriguez-Pardo D, et al. Data Mining Validation of Fluconazole Breakpoints Established by the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53:2949-54.
143. Cuesta I, Bielza C, Cuenca-Estrella M, Larranaga P, Rodriguez-Tudela JL. Evaluation by Data Mining techniques of Fluconazole Breakpoints established by the Clinical and Laboratory Standards Institute (CLSI), and its comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother. 2010;54:1541-6.
144. Rex JH, Pfaller MA,Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin Microbiol Rev. 2001;14:643-58. (Pubitemid 32979625)
145. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clin Microbiol Rev. 2006;19:435-47.
146. Barry AL, Pfaller MA, Rennie RP, Fuchs PC, Brown SD. Precision and accuracy of fluconazole susceptibility testing by broth microdilution. Etest, and disk diffusion methods. Antimicrob Agents Chemother. 2002;46:1781-4.
147. Canton E, Peman J, Espinel-Ingroff A, Martin-Mazuelos E, Carrillo-Munoz A, Martinez JP. Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. J Antimicrob Chemother. 2008;61:135-8.
148. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL. Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect. 2005;11:486-92. (Pubitemid 40744396)
149. Cuenca-Estrella M, Rodriguez-Tudela JL. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther. 2010;8:267-76.
150. Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC, Holliday N, Killian SB. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol. 2004;42:718-21. (Pubitemid 38222652)
151. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol. 2007;45:1811-20. (Pubitemid 46933912)
152. Gonzalez MT, Gonzalez A, Canton E, Aller AI, Romero A, Peman J, et al. Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method. Med Mycol. 2010.
153. Martos AI, Romero A, Gonzalez MT, Gonzalez A, Serrano C, Castro C, et al. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med Mycol. 2010.
154. Mendez CC, Serrano MC, Valverde A, Peman J, Almeida C, Martin-Mazuelos E. Comparison of E-Test, disk diffusion and a modified CLSI broth microdilution (M 38-A) method for in vitro testing of itraconazole, fluconazole and voriconazole against dermatophytes. Med Mycol. 2008;46:119-23. (Pubitemid 351372330)
155. Canton E, Espinel-Ingroff A, Peman J. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev Anti Infect Ther. 2009;7:107-19.